✦ LIBER ✦

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

✍ Scribed by F Caponigro; C Dittrich; J.B Sorensen; J.H.M Schellens; F Duffaud; L Paz Ares; D Lacombe; C de Balincourt; P Fumoleau

Book ID: 117657433
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 89 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)00336-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of DAC

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

✍ Twelves, C J; Gardner, C; Flavin, A; Sludden, J; Dennis, I; Bono, J de; Beale, P 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 92 KB

Phase II study of XR5000 (DACA), an inhi

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*

✍ Christian Dittrich; Veronique Dieras; Pierre Kerbrat; Cornelis Punt; Roberto Sor 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 65 KB

Phase II study of XR 5000 (DACA), an inh

Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer

✍ C Dittrich; B Coudert; L Paz-Ares; F Caponigro; M Salzberg; T Gamucci; X Paolett 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Phase I-II study of ftorafur and methyl-

Phase I-II study of ftorafur and methyl-ccnu in advanced colorectal cancer

✍ Robert J. Belt; Ronald Stephens 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 2 views

The combination of Ftorafur (NSC-148958) and methyl-CCNU (NSC-95441) was evaluated in 36 patients with advanced colorectal cancer. The principle toxicities encountered were myelosuppression, gastrointestinal, and neurological. There were no complete responses and only 5/34 (14.7%) patients achieved

937 Phase I trial of GL331, a novel topo

937 Phase I trial of GL331, a novel topoisomerase-II (T-II) inhibitor for advanced refractory cancer

✍ F.V. Fossella; R. Newman; K. Gorelick; M. Wester; A.Y. Kunz 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Phase II study of didemnin B in advanced

Phase II study of didemnin B in advanced colorectal cancer

✍ Dennie V. Jones; Jaffer A. Ajani; Roxann Blackburn; Karen Daugherty; Bernard Lev 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 222 KB